-
Board Certification
American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
5.0 /5( out of 61 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 18, 2024HUNTSMAN CANCER CENTERVery knowledgeable and takes the time to cover all aspects of your disease and treatment options.
October 03, 2024HUNTSMAN CANCER CENTERDr. Fashion makes me feel heard. He listens to my concerns and I feel I have a say in my treatment.
October 03, 2024HUNTSMAN CANCER CENTERIt was obvious from the first day Dr. Tashi knew my disease and what we could do about it.
September 06, 2024SOUTH JORDAN HEALTH CENTERDr. Tashi is wonderful. He cares so much for his patients. You can tell that he loves the work he does and the people he works with. He is so caring and considerate. I love seeing him. He is always so postive that you leave the exam room feeling like you're very valuable.
September 05, 2024SOUTH JORDAN HEALTH CENTERAbove and beyond care. He is very knowledgeable but kind and respectful He always gives me hope . Very positive. I love talking with him. Makes things possible.
September 05, 2024HUNTSMAN CANCER CENTERDr Tashi is a rock star. So happy he is there to help us with rare blood disorders.
July 29, 2024HUNTSMAN CANCER CENTERDr. Tashi is a great listener and he explained everything in a way that I could understand. I trust his expertise.
July 25, 2024HUNTSMAN CANCER CENTERDr Tashi was vey knowledgeable, informative, and helpful.
July 06, 2024HUNTSMAN CANCER CENTERExtraordinario profesional. Incisivo en la bΓΊsqueda del origen de tu condiciΓ³n mΓ©dica que te aqueja.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Hematology & Hematologic Malignancies
Board Certification American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Graduate Training Master of Science in Clinical Investigation - Ογ½ΆΚΣΖ΅ of Utah M.S.C.I Fellowship Hematology/Oncology - Ογ½ΆΚΣΖ΅ of Utah Fellow Residency Internal Medicine - Creighton Ογ½ΆΚΣΖ΅ Resident Residency Internal Medicine - Pingtung Christian Hospital Resident Internship Internal Medicine - MacKay Memorial Hospital Intern Professional Medical Medicine - Chang Gung Ογ½ΆΚΣΖ΅ School of Medicine M.D. Selected Publications
Journal Article
- Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid, 2(6), EVIDoa2200339. ()
- Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 23(1), 48. ()
- Chuah YY, Tashi T, Kuo CJ (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond), 83(11), 1. ()
- Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S342-S343. ()
- Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237. ()
- Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130. ()
Review
- Tashi T, Deininger MW (2023). Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. [Review]. Immunol Allergy Clin North Am, 43(4), 723-741. ()
- Tashi T (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. [Review]. Fed Pract, 39(Suppl 2), S43-S46. ()
Case Report
- Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80. ()
Editorial
- Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121. ()
-
News & Podcasts
-
Clinical Trials